June 26 (Reuters) - Altimmune Inc ALT.O:
ALTIMMUNE ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN THE TREATMENT OF MASH
ALTIMMUNE INC - TRIAL ACHIEVES 59.1% MASH RESOLUTION WITHOUT WORSENING FIBROSIS
ALTIMMUNE INC: TRIAL MET ITS PRIMARY ENDPOINT
ALTIMMUNE INC - WEIGHT LOSS OF UP TO 6.2% AT 24 WEEKS IN TRIAL
Source text: ID:nGNXp967x
Further company coverage: ALT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.